Evaluation of pandemic H1N1 (2009) influenza vaccine in adults with solid tumor and hematological malignancies on active systemic treatment.
J Clin Virol
; 50(3): 212-6, 2011 Mar.
Article
em En
| MEDLINE
| ID: mdl-21168361
ABSTRACT
BACKGROUND:
Over 85% of healthy individuals vaccinated with the pandemic H1N1 (pH1N1) vaccine achieve seroprotection.OBJECTIVES:
We evaluated the safety and immunogenicity of pH1N1 vaccine in patients undergoing chemotherapy for hematological and solid tumor malignancies. STUDYDESIGN:
Adult patients, receiving chemotherapy undergoing pH1N1 vaccination at our institution had blood samples drawn for CBC (baseline only) and serology prior to and ≥ 21 days post vaccination. HAI antibody testing was performed for pH1N1 (A/California/7/2009 strain) and seasonal H1 (A/Brisbane/59/07 strain). Seroprotection was defined as a pH1N1 antibody titre ≥ 140 and seroconversion as an antibody titre >4 × baseline. Patients completed a symptom diary card.RESULTS:
Paired samples were available for 46 patients (20 solid tumor, 26 hematological), median age 56 (range 23-76) years. The seroprotective rate post-vaccination for solid tumors was 50% compared to 27% for hematological malignancy (p=0.11), respective seroconversion rates were 45% and 19% (p=0.06). In patients with solid tumors vaccination mid cycle resulted in the highest pH1N1 titres, although timing and blood count were not associated with seroconversion or seroprotection. For hematological patients, a normal leukocyte count and vaccination at the beginning of a cycle were associated with higher rates of seroconversion (p ≤ 0.05). Addition of rituximab to chemotherapy resulted in a failure to seroconvert (p=0.05). Vaccination was well tolerated by all patients.CONCLUSIONS:
Although well tolerated, the seroprotection rate following pH1N1 vaccination is lower than that would be expected. Further investigation into immunization strategies in patients receiving chemotherapy is required.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Vacinas contra Influenza
/
Hospedeiro Imunocomprometido
/
Influenza Humana
/
Vírus da Influenza A Subtipo H1N1
/
Imunossupressores
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2011
Tipo de documento:
Article